Loading clinical trials...

A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis

A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients With Moderate to Severe Atopic Dermatitis

NCT05014438•Bristol-Myers Squibb

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986166 and of branebrutinib, each versus placebo, for the treatment of participants with moderate to severe atopic dermatitis.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Chronic atopic dermatitis (AD) diagnosed according to the Eichenfield modification of Hanifin's and Rajka's (E-HR) criteria at Screening
•Disease duration of at least 24 months since diagnosis by any criteria
•Documented history of inadequate control of AD by a stable regimen (≥ 4 weeks) of topical corticosteroids, calcineurin inhibitors or biologics, within 6 months of randomization, or inappropriateness of therapy due to side effects or safety risks leading to prior discontinuation
•Application of fixed doses of an additive-free, basic bland emollient twice-daily for ≥ 7 days before baseline visit and for the duration of the study

Exclusion Criteria

•Any major illness/condition or evidence of an unstable clinical condition or local active infection/infectious illness that, in the investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study or interfere with the interpretation of study results
•Clinically relevant cardiovascular conditions or pulmonary conditions
•High likelihood - based on participant history, and investigator judgement - of requiring rescue therapy in \< 4 weeks prior to randomization
•Evidence of acute flare between the Screening and Baseline/ Randomization
•Skin lesion(s) and/or pruritus due to conditions other than AD that would interfere with the study specified assessments

Locations (42)

Local Institution - 0091

Fremont, California, United States

Local Institution - 0112

Brandon, Florida, United States

Local Institution - 0061

Coral Gables, Florida, United States

Local Institution - 0110

Margate, Florida, United States

Local Institution - 0006

Miami Lakes, Florida, United States

Local Institution

Tampa, Florida, United States

Local Institution - 0008

Skokie, Illinois, United States

Local Institution - 0081

Indianapolis, Indiana, United States

Local Institution - 0083

Louisville, Kentucky, United States

Dermatology and Skin Cancer Specialists, LLC

Rockville, Maryland, United States

Key Dates

Start Date

August 17, 2021

Primary Completion Date

August 22, 2022

Completion Date

August 22, 2022

Last Updated

October 18, 2023

Enrollment

ACTUAL participants

Conditions

Dermatitis, Atopic

Interventions

BMS-986166

DRUG

Branebrutinib

DRUG

Placebo

OTHER

The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis

NCT06488742

Dermatitis, AtopicPruritus

View study

TERMINATED

A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT05250115

Dermatitis, Atopic

View study

COMPLETEDPHASE2

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 18, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis

Inclusion Criteria

Exclusion Criteria

The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis

A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

Effect of Benralizumab in Atopic Dermatitis

Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2)

Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis

Stabilized Whole Rice Bran (SWRB) for Mild to Moderate Atopic Dermatitis